沙利度胺联合化疗治疗骨转移去势抵抗性前列腺癌的疗效观察

发布时间：2018-03-27 09:47

本文选题：去势抵抗性前列腺癌　切入点：骨转移　出处：《中国癌症杂志》2017年04期

【摘要】：背景与目的:多西他赛联合泼尼松治疗可延长转移性去势抵抗性前列腺癌患者的生存期,血管生成抑制剂也可抑制肿瘤生长,联合治疗的疗效目前仍不明确。该研究旨在观察沙利度胺联合多西他赛和泼尼松治疗骨转移的去势抵抗性前列腺癌的近期临床疗效。方法:收集2008年12月—2015年6月南京军区福州总医院收治的骨转移去势抵抗性前列腺癌患者78例,其中40例作为对照组给予多西他赛和泼尼松方案化疗,38例作为观察组在对照组的基础上给予沙利度胺联合化疗,观察两组有效率、骨痛缓解率、前列腺特异性抗原(prostate specific antigen,PSA)无进展时间、无疾病进展时间及总生存时间,并评价不良反应。结果:观察组有效率为65.79%,PSA无进展时间为4.13个月,无疾病进展时间为4.25个月,骨痛缓解率为86.84%;对照组有效率为40.00%,PSA无进展时间为3.54个月,无疾病进展时间为3.75个月,骨痛缓解率为60.00%,观察组均高于对照组,差异有统计学意义(P0.05)。治疗后两组总生存时间、患者恶心呕吐及白细胞下降等不良反应发生率比较,差异无统计学意义(P0.05)。结论:沙利度胺联合化疗治疗骨转移的去势抵抗性前列腺癌近期临床效果满意,安全,不增加不良反应,具有较高的临床应用价值。
[Abstract]:Background & objective: docetaxel combined with prednisone can prolong the survival of patients with metastatic ovariectomized prostate cancer, and angiogenesis inhibitors can also inhibit tumor growth. The efficacy of combination therapy is still unclear. The aim of this study was to observe the short-term clinical efficacy of thalidomide combined with docetaxel and prednisone in the treatment of Ovariectomized prostate cancer with bone metastasis. Seventy-eight patients with bone metastases and ovariectomized prostate cancer were admitted to Fuzhou General Hospital of Nanjing military region in June. 40 cases were treated with docetaxel and prednisone regimen chemotherapy and 38 cases were treated with thalidomide combined chemotherapy on the basis of control group. The effective rate and bone pain relief rate were observed. There was no progression time, no disease progression time and total survival time, and adverse reactions were evaluated. Results: the effective rate of the observation group was 4.13 months and 4.25 months, respectively. The remission rate of bone pain was 86.84, the effective rate of the control group was 40.005 months, the progress time of PSA was 3.54 months, the time of no disease progression was 3.75 months, and the remission rate of bone pain was 60.00.The difference between the two groups was statistically significant (P 0.05), and the total survival time of the two groups was significantly higher than that of the control group. There was no significant difference in the incidence of adverse reactions such as nausea and vomiting and leukopenia. Conclusion: thalidomide combined with chemotherapy is safe and effective in the treatment of ovariectomized prostate cancer with bone metastasis. It has high clinical application value without increasing adverse reactions.
【作者单位】：南京军区福州总医院放疗科;南京军区福州总医院医务部;
【基金】：福建省自然科学基金资助项目(2016J05198) 中华医学基金会(314·2213) 福建医科大学启航基金(2016QH129)
【分类号】：R737.25

【参考文献】